Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch of its new website at www.tharimmune.com. This redesigned online platform provides patients, healthcare professionals and stakeholders with comprehensive information about Tharimmune's cutting-edge research, ongoing clinical trials and corporate developments.
"Our new website represents a valuable resource in our commitment to engage with the broader medical community and our investors," said Randy Milby, CEO of Tharimmune. "We believe this platform enhances our ability to communicate our mission and progress, as well as foster stronger connections with all our stakeholders."
The new website features a user-friendly interface, detailed sections on Tharimmune's pipeline of investigational therapies, including its lead candidate, TH104, and resources for patients and caregivers. Visitors will also find the latest news and updates, company-produced content, scientific publications, upcoming events and opportunities for collaboration.
In tandem with the launch of the new website and following a productive Type C meeting with the U.S. Food and Drug Administration (FDA), Tharimmune is continuing discussions with the FDA, regarding the study design and initiation of a Phase 2 clinical trial for TH104 in moderate-to-severe chronic pruritis in primary biliary cholangitis.
"These ongoing discussions have been valuable in shaping the design of the next study and are a critical step in advancing the development of our promising therapy, which has the potential to address a large unmet medical need. We expect to launch the Phase 2 trial in the third quarter of this year," added Mr. Milby.
About TH104
TH104 is embedded with nalmefene onto a proprietary transmucosal buccal film that easily adheres to the inside of the mouth. This dosage form endows TH104 with key features making it an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The molecule has a dual mechanism of action affecting both the µ-opioid and kappa opioid receptors. These opioid receptors when stimulated and/or inhibited by the body's natural ligands have been known to be involved in the body's itch circuitry.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immunology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors, including PD-1, HER2 and HER3. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against these and other specified targets.
No comments:
Post a Comment